What Is TAC1? Definition and What Research Reports

TAC1 stands for tachykinin precursor 1. It is a gene — written TAC1 for the human gene and Tac1 for the mouse and rat versions — not a peptide that can be held in a vial. The gene encodes a precursor protein (protachykinin-1) that cells cut into several short signalling peptides of the tachykinin family, the best known of which is substance P. Because the gene is switched on in a restricted set of neurons and immune cells, laboratories also use "Tac1" as a molecular label: a way of identifying, imaging or switching on and off the particular cells that express it. That dual meaning — a peptide precursor gene and a cell-type marker — is why the term turns up so often in modern circuit-neuroscience papers.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. Nothing here describes how any substance should be used.

What class of molecule TAC1 produces

Tachykinins are a family of short peptides that share a conserved C-terminal motif and act at G-protein-coupled neurokinin receptors. Substance P, the principal TAC1 product, was described as an 11-amino-acid undecapeptide that signals mainly through the neurokinin-1 receptor (NK1R) and is distributed widely through the central and peripheral nervous systems in a review of substance P biochemistry (PMID 32119470). The same review reported roles for substance P in pain transmission, inflammation, smooth-muscle activity and vomiting, which explains why the gene surfaces across such different research fields (PMID 32119470).

How the term is used in peptide and neuroscience research

In peptide pharmacology, TAC1 is usually invoked as the source of substance P and neurokinin A. In systems neuroscience, the usage is different: "Tac1" names a cell population. Researchers cross Tac1-Cre mouse lines with reporter or actuator genes so that only Tac1-expressing neurons carry a fluorescent tag, a calcium sensor, or an opsin. Findings in these papers are therefore statements about a genetically defined cell type, not about administering a peptide. Readers scanning abstracts will see phrasing such as "Tac1⁺ neurons in the dorsal vagal complex" or "Tac1 lineage spinal neurons"; in both cases the gene is functioning as an address label.

Nausea, retching and gut-to-brain circuits

Some of the most cited recent TAC1 work concerns defensive responses to ingested toxins. A 2022 Cell study mapped a gut-to-brain axis in mice and reported that bacterial toxin exposure recruited enterochromaffin-cell and vagal signalling onto area postrema and dorsal vagal complex neurons, with Tac1-expressing neurons among the populations driving retching-like defensive behaviours (PMID 36323317). A 2024 paper in National Science Review subsequently examined brain circuits for retching-like behaviour and discussed how these brainstem pathways are organised (PMID 38288368). Both reports are anatomical and circuit-level work in animals; neither described a peptide product given to humans.

Sensory neurons, pain and itch

TAC1 is a classical marker of peptidergic nociceptors. A 2025 preprint investigated a molecular and spinal circuit basis for the functional segregation of itch and pain and reported that genetically defined spinal populations separated the two modalities rather than sharing a single labelled line (PMID 40766363). Work on visceral innervation identified lung-innervating sensory neurons and reported that molecularly distinct subsets, including peptidergic populations, showed target specificity within the airway (PMID 34755535). On the human side, a 2023 protocol paper described the scalable generation of sensory neurons from human pluripotent stem cells and reported that the derived cells expressed nociceptor identity markers, providing a human-cell platform in which tachykinin expression can be studied (PMID 37044067).

Neuroimmune signalling

Substance P is one of the cationic peptides linked to mast-cell activation, which is why TAC1 appears in immunology literature. A 2024 study examined mast cell MrgprB2 in neuroimmune interaction during IgE-mediated airway inflammation and reported that the receptor contributed to that interaction and that signalling was modulated by β-arrestin2 (PMID 39483467). The study is about receptor biology in mice, not about peptide administration.

Motivated and defensive behaviour

Tachykinin-marked neurons have also been used to dissect behavioural circuits. A 2023 Cell paper described a neural circuit for male sexual behaviour and reward in mice and reported that a genetically defined hypothalamic-to-forebrain pathway was sufficient to drive the behaviour and its reinforcing properties (PMID 37572660). This line of work illustrates the general pattern: marker genes such as Tac1 give access to circuits, and the resulting claims are about the circuits.

TAC1 in fungal biology: a different gene with the same name

Anyone searching the abbreviation will also encounter TAC1 in Candida genetics, where it stands for transcriptional activator of CDR genes and has no relationship to tachykinins. A 2023 review of molecular mechanisms associated with antifungal resistance in pathogenic Candida species reported that gain-of-function mutations in transcription factors such as TAC1 drive overexpression of drug-efflux pumps and contribute to azole resistance (PMID 37998390). The two genes share only an acronym.

TAC1 signalling and adverse physiology: what studies report

Because TAC1 is a gene rather than a product that is administered, the literature does not contain adverse-event tables of the kind seen for investigational compounds. What researchers have described instead are physiological consequences of tachykinin signalling. The substance P review reported associations with pain signalling, inflammatory responses and emesis (PMID 32119470), and the 2022 gut-to-brain study reported that activation of the identified brainstem pathway produced retching-like defensive behaviour in mice (PMID 36323317). Mast-cell work reported that MrgprB2-dependent neuroimmune signalling contributed to airway inflammation in an IgE-mediated mouse model (PMID 39483467). These are mechanistic observations in animal and cell systems, not safety data about any product.

Limits of the evidence

• Species. Most of the circuit findings cited above were obtained in mice, and the human stem-cell work described a cell-culture model rather than a clinical population (PMID 37044067).
• Marker versus peptide. A finding about Tac1-expressing neurons does not automatically mean the substance P peptide caused the effect; the gene identifies the cell.
• Preprints. At least one of the itch-versus-pain reports was a preprint and had not completed peer review at the time of posting (PMID 40766363).
• Ambiguity. Database searches return both the mammalian tachykinin gene and the unrelated fungal transcription factor (PMID 37998390).

Related terms

• Tachykinin — the peptide family that includes substance P and neurokinin A.
• NK1R (TACR1) — the principal receptor for substance P described in the biochemistry review (PMID 32119470).
• TAC3 / TAC4 — separate genes encoding other tachykinins such as neurokinin B and hemokinin-1.
• Tac1-Cre — the transgenic tool line used to access Tac1-expressing neurons in rodent studies.

References

• Biochemistry, Substance P (StatPearls, 2026)
• The gut-to-brain axis for toxin-induced defensive responses (Cell, 2022)
• Brain circuits for retching-like behavior (National Science Review, 2024)
• A molecular and spinal circuit basis for the functional segregation of itch and pain (bioRxiv, 2025)
• Identification of lung innervating sensory neurons and their target specificity (American Journal of Physiology. Lung Cellular and Molecular Physiology, 2022)
• Scalable generation of sensory neurons from human pluripotent stem cells (Stem Cell Reports, 2023)
• Mast cell MrgprB2 in neuroimmune interaction in IgE-mediated airway inflammation and its modulation by β-arrestin2 (Frontiers in Immunology, 2024)
• A neural circuit for male sexual behavior and reward (Cell, 2023)
• Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species (Cells, 2023)